Blending fantasy and science fiction, N. E. Davenport’s fast-paced, action-packed debut kicks off a duology of loyalty and rebellion, in which a young Black woman must survive deadly trials in a racist and misogynistic society to become an elite warrior. It’s all about blood. The blood spilled between the Republic of Mareen and the armies of the Blood Emperor long ago. The blood gifts of Mareen’s deadliest enemies. The blood that runs through the elite War Houses of Mareen, the rulers of the Tribunal dedicated to keeping the republic alive. The blood of the former Legatus, Verne Amari, murdered. For his granddaughter, Ikenna, the only thing steady in her life was the man who had saved Mareen. The man who had trained her in secret, not just in martial skills, but in harnessing the blood gift that coursed through her. Who trained her to keep that a secret. But now there are too many secrets, and with her grandfather assassinated, Ikenna knows two things: that only someone on the Tribunal could have ordered his death, and that only a Praetorian Guard could have carried out that order. Bent on revenge as much as discovering the truth, Ikenna pledges herself to the Praetorian Trials—a brutal initiation that only a quarter of the aspirants survive. She subjects herself to the racism directed against her half-Khanaian heritage and the misogyny of a society that cherishes progeny over prodigy, all while hiding a power that—if found out—would subject her to execution…or worse. Ikenna is willing to risk it all because she needs to find out who murdered her grandfather…and then she needs to kill them. Mareen has been at peace for a long time… Ikenna joining the Praetorians is about to change all that. Magic and technology converge in the first part of this stunning debut duology, where loyalty to oneself—and one’s blood—is more important than anything.

She’s spent her life trying not to become the monster they think she is…But what if a monster is exactly what they need? Injured and hunted, Jade is forced to flee the Northwind Pack’s territory and leave her mate, Darren Power, behind. But she’s been followed, and a hunter has his sights set on Jade, and he isn’t afraid to hurt those she loves to get to her. Finding herself backed into a corner, Jade is left with two options–run to draw the danger away from her friends or accept the help of her sworn enemy–for a price. What Jade doesn’t know is that Darren knows she’s in danger, and he won’t rest until she’s safe. But the rogues aren’t the only ones that call the mountain forests their home, and Darren is far from prepared for the dangers he’ll face on his quest to find Jade and right his father’s mistakes. Hunters, witches, betrayal, and forgotten legends are around every corner, and Darren and Jade are about to learn that the truth isn’t always what it seems. Can they let go of their pasts and what they know to find the truth before it’s too late? Blood Trials is the second book in The Blood Wolf Trilogy, a YA paranormal romance

Living life as an insulin-dependent diabetic should not be without hope. A full, rich, and healthy life can be yours when you learn how to properly manage your disease. But there's so much information out there, it's hard to know what to trust. Even the doctors and specialists can't agree on what's best some days. If you find all the medical books and jargon confusing, this book was written for you. Author Ethereal T. Henry Jr. is not a doctor or a diabetes educator. He wouldn't call himself an expert. What he is, however, is a person who has found a way to live his life with type-1 diabetes, and that's an accomplishment worth learning more about. Here, he shares the details of his day-to-day experiences and the solutions he, as a patient, has found. He explains some of the problems you might encounter and how he's learned to deal with them. He's proven that there is hope, and he shares his secrets with you here. This person-to-person guide to how one man managed his disease may inspire you to find your own path to happiness and health.

Trials to Triumph is the autobiography of Arthur "Flash" Johnson. Journey with him through his physical and spiritual bouts, as he grows from poverty in East Saint Louis to prominence in the Olympic boxing ring. Sit with him as fights Leukemia in the quietness of the hospital room long after the crowds are gone, and be inspired by his faith in God, which brought him from Trials to Triumph time and time again.

Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines is a practical guidebook for those engaged in clinical trial design. This book details the organizations and content of clinical trials, including trial design, safety, endpoints, subgroups, HRQoL, consent forms and package inserts. It provides extensive information on both US and international regulatory guidelines and features concrete examples of study design from the medical literature. This book is intended to orient those new to clinical trial design and provide them with a better understanding of how to conduct clinical trials. It will also act as a guide for the more experienced by detailing endpoint selection and illustrating how to avoid unnecessary pitfalls. This book is a straightforward and valuable reference for all those involved in clinical trial design. Provides extensive coverage of the "study schema" and related features of study design Offers a "hands-on" reference that contains an overview of the process, but more importantly details a step-by-step account of clinical trial design Features examples from the medical literature to highlight how investigators choose the most suitable endpoint(s) for clinical trial and includes graphs from real clinical trials to help explain each concept in study design Integrates clinical trial design, pharmacology, biochemistry, cell biology and legal aspects to provide readers with a comprehensive look at all aspects of clinical trials Includes chapters on core material and important ancillary topics, such as package inserts, consent forms, and safety reporting forms used in the United States, England and Europe For complimentary access to our sample chapter (chapter 24), please copy and paste this link into your browser: http://tinyurl.com/awwutvn

In June 1993 a clinical trial of fialuridine (FIAU), a promising new medication for hepatitis B, was abruptly terminated when one of the 15 out-patients participating in the National Institutes of Health (NIH) study was suddenly hospitalized with liver failure. Although all the remaining patients were contacted and told to stop taking their medication, six more subsequently developed severe toxicity. Five patients died, and two others were probably saved from death only by having liver transplants. In response to a request from the Secretary of the Department of Health and Human Services, the IOM committee has analyzed the FIAU clinical trials, making recommendations for additional safeguards for the conduct of future clinical trials. This evaluation included the review of documents pertaining to investigational new drug submissions, protocols and consent forms from other clinical trials, as well as information available from other clinical and preclinical experience with compounds related to FIAU and its parent drug, fiacitibine (FIAC), which is metabolized to FIAU. The committee does not seek to affix responsibility for the adverse outcome of this NIH trial, but instead focuses on whether any rules or procedures governing the clinical trials process itself need to be changed, and if so, what burdens or costs such changes might place on future clinical trials.